- Home
- EMD vs CBIO Comparison
EMD vs CBIO Comparison
Compare EMD & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | EMD | CBIO |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 626.1M | 557.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EMD | CBIO |
|---|---|---|
| Price | $10.42 | $18.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 198.6K | ★ 269.6K |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $279.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.60 | $8.72 |
| 52 Week High | $11.30 | $27.41 |
Technical Indicators
Market Signals| Indicator | EMD | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 45.39 | 45.87 |
| Support Level | $10.19 | $16.31 |
| Resistance Level | $10.65 | $21.60 |
| Average True Range (ATR) | 0.17 | 1.78 |
| MACD | -0.02 | -0.30 |
| Stochastic Oscillator | 33.27 | 27.80 |
Price Performance
Historical ComparisonAbout EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management and long term investment company. The primary investment objective of the company is to seek high current income, and the secondary objective is to seek capital appreciation.
About CBIO Crescent Biopharma Inc.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.